Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kalvista Pharmaceuticals Inc

15.30
-0.3034-1.94%
Volume:391.88K
Turnover:6.06M
Market Cap:761.19M
PE:-4.14
High:15.63
Open:15.63
Low:15.20
Close:15.60
Loading ...

Kalvista Pharmaceuticals Inc. Announces Resignation of Chief Operating Officer Jebediah T. Ledell

Reuters
·
13 May

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
02 May

KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

Business Wire
·
30 Apr

KalVista Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham

Dow Jones
·
08 Apr

KalVista Signs Deal With Kaken to Commercialize Hereditary Angioedema Treatment in Japan

MT Newswires Live
·
08 Apr

BRIEF-Kalvista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical To Commercialize Sebetralstat For HAE In Japan

Reuters
·
08 Apr

KalVista Pharmaceuticals Price Target Maintained With a $19.00/Share by Citizens Capital Markets

Dow Jones
·
26 Mar

KalVista Pharmaceuticals Is Maintained at Buy by Jones Trading

Dow Jones
·
26 Mar

KalVista completes enrollment in KONFIDENT-KID clinical trial of sebetralstat

TIPRANKS
·
26 Mar

KalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial

MT Newswires Live
·
25 Mar

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

Business Wire
·
25 Mar

KalVista Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Mar

KalVista Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham

Dow Jones
·
13 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
11 Mar

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

Business Wire
·
10 Mar

Kalvista Pharmaceuticals Inc expected to post a loss of 87 cents a share - Earnings Preview

Reuters
·
07 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 Mar

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
04 Mar

KalVista Pharmaceuticals Price Target Maintained With a $19.00/Share by Citizens Capital Markets

Dow Jones
·
03 Mar

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Business Wire
·
03 Mar